Who owns Xeris Biopharma Holdings, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of XERS from SEC Form 13F filings across 249 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 249 institutions disclosed 113.4M shares of Xeris Biopharma Holdings, Inc. worth $1.08B — about 62.6% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
249
13F holders
$1.08B
value, 2026 filers
62.6%
of shares outstanding (113.4M sh)
35
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of XERS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 14.7M | $140.1M | 0.0% | 8.1% | +0.9% |
| 2 | D. E. Shaw & Co., Inc. | 8.0M | $76.3M | 0.0% | 4.4% | +2.2% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 7.7M | $73.7M | 0.0% | 4.3% | +5.0% |
| 4 | STATE STREET CORP | 5.6M | $53.3M | 0.0% | 3.1% | +15.6% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 4.6M | $43.7M | 0.0% | 2.5% | -3.1% |
| 6 | Nuveen, LLC | 4.1M | $39.6M | 0.0% | 2.3% | -5.5% |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.6M | $25.3M | 0.0% | 1.5% | +0.9% |
| 8 | Rosalind Advisors, Inc. | 2.6M | $24.7M | 7.9% | 1.4% | -11.2% |
| 9 | MORGAN STANLEY | 2.6M | $24.7M | 0.0% | 1.4% | +10.4% |
| 10 | Qube Research & Technologies Ltd | 2.5M | $23.7M | 0.0% | 1.4% | -14.4% |
| 11 | JPMORGAN CHASE & CO | 2.4M | $23.8M | 0.0% | 1.3% | +125.1% |
| 12 | Point72 Asset Management, L.P.NEW | 2.1M | $20.3M | 0.0% | 1.2% | new |
| 13 | WELLINGTON MANAGEMENT GROUP LLP | 2.1M | $19.7M | 0.0% | 1.1% | -12.8% |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.9M | $17.7M | 0.0% | 1% | +24.0% |
| 15 | JACOBS LEVY EQUITY MANAGEMENT, INCNEW | 1.7M | $16.6M | 0.1% | 1% | new |
| 16 | DIMENSIONAL FUND ADVISORS LP | 1.7M | $16.2M | 0.0% | 0.9% | +57.9% |
| 17 | GOLDMAN SACHS GROUP INC | 1.7M | $15.8M | 0.0% | 0.9% | +4.0% |
| 18 | Parkman Healthcare Partners LLC | 1.6M | $15.7M | 1.4% | 0.9% | -9.1% |
| 19 | Legal & General Group Plc | 1.6M | $15.5M | 0.0% | 0.9% | -19.6% |
| 20 | NORTHERN TRUST CORP | 1.6M | $15.4M | 0.0% | 0.9% | +1.1% |
| 21 | AQR CAPITAL MANAGEMENT LLC | 1.6M | $15.0M | 0.0% | 0.9% | +1.9% |
| 22 | FEDERATED HERMES, INC. | 1.5M | $14.6M | 0.0% | 0.8% | +6.2% |
| 23 | ARMISTICE CAPITAL, LLC | 1.5M | $14.2M | 0.2% | 0.8% | -23.9% |
| 24 | FIRST TRUST ADVISORS LP | 1.4M | $13.4M | 0.0% | 0.8% | +189.4% |
| 25 | VANGUARD FIDUCIARY TRUST CO | 1.3M | $12.3M | 0.0% | 0.7% | +4.8% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.